Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α

Indian Heart Journal

Volumn 66, Issue 6, 2014, Pages 574-579

  Ajmal, Masihur Rehman ^a   Yaccha, Monika ^b   Malik, Mohammed Azharuddin ^a   Rabbani, M U ^a   Ahmad, Ibne ^a   Isalm, Najmul ^a   Abdali, Nasar ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cardiovascular disease; hs CRP; NAFLD; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; COMPLICATION; INDIA; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921650388     PISSN: 00194832     EISSN: 22133763     Source Type: Journal    
DOI: 10.1016/j.ihj.2014.08.006     Document Type: Article

References (28)

1. G.C. Farrell, J. George, P. Hall, M. de la, and A.J. McCullough Fatty Liver Disease: NASH and Related Disorders 2005 Blackwell Publishing
2. G.C. Farrell, and C.Z. Larter Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatol Balt Md 43 2 Suppl 1 2006 S99 S112 10.1002/hep.20973
3. G. Marchesini, R. Marzocchi, F. Agostini, and E. Bugianesi Nonalcoholic fatty liver disease and the metabolic syndrome Curr Opin Lipidol 16 2005 421 427
4. B.A. Neuschwander-Tetri Nonalcoholic steatohepatitis and the metabolic syndrome Am J Med Sci 330 2005 326 335
5. K.-H. Yoon, J.-H. Lee, and J.-W. Kim Epidemic obesity and type 2 diabetes in Asia Lancet 368 2006 1681 1688 10.1016/S0140-6736(06)69703-1
6. J.-G. Fan, J. Zhu, and X.-J. Li Prevalence of and risk factors for fatty liver in a general population of Shanghai, China J Hepatol 43 2005 508 514 10.1016/j.jhep.2005.02.042
7. J.-G. Fan, T. Saibara, and S. Chitturi What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 22 2007 794 800 10.1111/j.1440-1746.2007.04952.x
8. D.N. Amarapurkar, E. Hashimoto, and L.A. Lesmana How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22 2007 788 793 10.1111/j.1440-1746.2007.05042.x
9. V. Mohan, M. Deepa, and R. Deepa Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India-the Chennai Urban Rural Epidemiology Study (CURES-17) Diabetologia 49 2006 1175 1178 10.1007/s00125-006-0219-2
10. M. Ekstedt, L.E. Franzén, and U.L. Mathiesen Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatol Balt Md 44 2006 865 873 10.1002/hep.21327
11. G. Targher, F. Marra, and G. Marchesini Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51 2008 1947 1953 10.1007/s00125-008-1135-4
12. L.F. Van Gaal, I.L. Mertens, and C.E. De Block Mechanisms linking obesity with cardiovascular disease Nature 444 2006 875 880 10.1038/nature05487
13. S.E. Shoelson Inflammation and insulin resistance J Clin Invest 116 2006 1793 1801 10.1172/JCI29069
14. M. Yoneda, H. Mawatari, and K. Fujita High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH J Gastroenterol 42 2007 573 582 10.1007/s00535-007-2060-x
15. A.E. Feldstein, N.W. Werneburg, and A. Canbay Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway Hepatol Balt Md 40 2004 185 194 10.1002/hep.20283
16. J.M. Hui, A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, and J. George Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatol Balt Md 40 2004 46 54 10.1002/hep.20280
17. M.T. Schram, N. Chaturvedi, C.G. Schalkwijk, J.H. Fuller, C.D.A. Stehouwer EURODIAB Prospective Complications Study Group Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study Diabetologia 48 2005 370 378 10.1007/s00125-004-1628-8
18. S. Maumus, B. Marie, G. Siest, and S. Visvikis-Siest A prospective study on the prevalence of metabolic syndrome among healthy French families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome Diabetes Care 28 2005 675 682
19. E. Lopez-Garcia, M.B. Schulze, and J.B. Meigs Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction J Nutr 135 2005 562 566
20. G. Targher, L. Bertolini, and L. Scala Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis Diabetes Care 30 2007 e31 e32 10.2337/dc07-0109
21. J.A. Welsh, S. Karpen, and M.B. Vos Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010 J Pediatr 162 2013 10.1016/j.jpeds.2012.08.043 496-500.e1
22. R.J. Prineas, R.S. Crow, and Z. Zhang The Minnesota Code Manual of Electrocardiographic Findings 2009 Springer
23. H. Keen, and R.J. Jarrett The WHO multinational study of vascular disease in diabetes: 2. Macrovascular disease prevalence Diabetes Care 2 1979 187 195
24. G. Targher Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease J Hepatol 45 2006 879 881
25. N. Rifai High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome Clin Chem 51 2005 504 505 10.1373/clinchem.2004.044990
26. G. Targher, L. Bertolini, and S. Rodella NASH predicts plasma inflammatory biomarkers independently of visceral fat in men Obes Silver Spring Md 16 2008 1394 1399 10.1038/oby.2008.64
27. J. Lizardi-Cervera, N.C. Chavez-Tapia, O. Pérez-Bautista, M.H. Ramos, and M. Uribe Association among C-reactive protein, fatty liver disease, and cardiovascular risk Dig Dis Sci 52 2007 2375 2379 10.1007/s10620-006-9262-6
28. H. Yong-hong The relationship of tumor necrosis factor-alpha and non-alcoholic fatty liver diseases complicated with metabolic syndrome J Youjiang Med Coll Natl 2 2009 013